Mesoblast Limited (ADR)
General ticker "MESO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
Mesoblast Limited (ADR) follows the US Stock Market performance with the rate: 2.6%.
Estimated limits based on current volatility of 2.6%: low 13.42$, high 14.15$
Factors to consider:
- Total employees count: 108 (+33.3%) as of 2026
- Current price 24.6% above estimated high
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [6.09$, 13.19$]
- 2026-06-30 to 2027-06-30 estimated range: [4.69$, 10.66$]
Financial Metrics affecting the MESO estimates:
- Positive: with PPE of -7.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: 1.42 < Interest expense per share per price, % of 1.79
- Negative: 69.38 < Shareholder equity ratio, % of 76.14 <= 81.92
- Negative: Investing cash flow per share per price, % of 0.01 <= 2.08
- Negative: negative Industry operating cash flow (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: Inventory ratio change, % of 56.40 > 4.02
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -21.42 <= 0
Short-term MESO quotes
Long-term MESO plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $5.90MM | $17.20MM | $120.79MM |
| Operating Expenses | $90.05MM | $79.64MM | $172.29MM |
| Operating Income | $-84.15MM | $-62.44MM | $-51.50MM |
| Non-Operating Income | $-4.00MM | $-39.37MM | $-5.64MM |
| Interest Expense | $20.66MM | $22.93MM | $23.95MM |
| R&D Expense | $25.35MM | $34.81MM | $97.94MM |
| Income(Loss) | $-88.15MM | $-101.81MM | $-57.14MM |
| Taxes | $-0.19MM | $0.33MM | $0.62MM |
| Net Income(Loss)* | $-87.96MM | $-102.14MM | $-115.51MM |
| Stockholders Equity | $480.36MM | $597.44MM | $568.40MM |
| Inventory | $0.00MM | $22.25MM | $28.11MM |
| Assets | $669.15MM | $784.68MM | $773.08MM |
| Operating Cash Flow | $-48.46MM | $-49.95MM | $-43.83MM |
| Capital expenditure | $0.33MM | $0.73MM | $0.90MM |
| Investing Cash Flow | $-0.10MM | $0.12MM | $-1.02MM |
| Financing Cash Flow | $40.25MM | $147.34MM | $-15.33MM |
| Earnings Per Share** | $-0.89 | $-0.85 | $-0.89 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.